Obesity Drug Stocks Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:20
Jan 21
Jan 21
Obesity and R&D biotech attractive.
Selected Korean biotech names tied to obesity drugs and R&D remain fundamentally positive and can be bought on weakness.
MED
03:20
Jan 21
Jan 21
Watch quality Korean biotech.
Korean biotech is pressured by macro and Alteogen's royalty miss, but companies with solid technology-export pipelines and obesity-drug exposure should be watched for recovery.
MED
About Obesity Drug Stocks Investor Commentary
Across the available history and selected sources, Buzzberg tracks Obesity Drug Stocks across 1 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Park Geun-hyung, Bae Jae-won.